Last reviewed · How we verify

recombinant 70-kD heat-shock protein

Memorial Sloan Kettering Cancer Center · Phase 1 active Biologic Quality 0/100

recombinant 70-kD heat-shock protein is a Biologic drug developed by Memorial Sloan Kettering Cancer Center. It is currently in Phase 1 development.

At a glance

Generic namerecombinant 70-kD heat-shock protein
SponsorMemorial Sloan Kettering Cancer Center
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about recombinant 70-kD heat-shock protein

What is recombinant 70-kD heat-shock protein?

recombinant 70-kD heat-shock protein is a Biologic drug developed by Memorial Sloan Kettering Cancer Center.

Who makes recombinant 70-kD heat-shock protein?

recombinant 70-kD heat-shock protein is developed by Memorial Sloan Kettering Cancer Center (see full Memorial Sloan Kettering Cancer Center pipeline at /company/memorial-sloan-kettering-cancer-center).

What development phase is recombinant 70-kD heat-shock protein in?

recombinant 70-kD heat-shock protein is in Phase 1.

Related